Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis.
| Autor: | Bradley, John S, Bulitta, Jürgen B, Cook, Rachel, Yu, Patricia A, Iwamoto, Chelsea, Hesse, Elisabeth M, Chaney, Danielle, Yu, Yon, Kennedy, Jordan L, Sue, David, Karchmer, Adolf W, Bower, William A, Hendricks, Katherine |
|---|---|
| Předmět: |
CIPROFLOXACIN
PENICILLIN G RESEARCH funding ANTHRAX meningitis CENTRAL nervous system AMPICILLIN DOXYCYCLINE DESCRIPTIVE statistics ANTI-infective agents DOSE-effect relationship in pharmacology SIMULATION methods in education QUINOLONE antibacterial agents VANCOMYCIN CLINDAMYCIN AMIKACIN CILASTATIN MINOCYCLINE LINEZOLID CEREBROSPINAL fluid MEROPENEM PENICILLIN |
| Zdroj: | Clinical Infectious Diseases; 6/15/2024, Vol. 78 Issue 6, p1451-1457, 7p |
| Abstrakt: | Background The high mortality of systemic anthrax is likely a consequence of the severe central nervous system inflammation that occurs in anthrax meningitis. Effective treatment of such infections requires, at a minimum, adequate cerebrospinal fluid (CSF) antimicrobial concentrations. Methods We reviewed English medical literature and regulatory documents to extract information on serum and CSF exposures for antimicrobials with in vitro activity against Bacillus anthracis. Using CSF pharmacokinetic exposures and in vitro B. anthracis susceptibility data, we used population pharmacokinetic modeling and Monte Carlo simulations to determine whether a specific antimicrobial dosage would likely achieve effective CSF antimicrobial activity in patients with normal to inflamed meninges (ie, an intact to markedly disrupted blood–brain barrier). Results The probability of microbiologic success at achievable antimicrobial dosages was high (≥95%) for ciprofloxacin, levofloxacin (500 mg every 12 hours), meropenem, imipenem/cilastatin, penicillin G, ampicillin, ampicillin/sulbactam, doxycycline, and minocycline; acceptable (90%–95%) for piperacillin/tazobactam and levofloxacin (750 mg every 24 hours); and low (<90%) for vancomycin, amikacin, clindamycin, and linezolid. Conclusions Prompt empiric antimicrobial therapy of patients with suspected or confirmed anthrax meningitis may reduce the high morbidity and mortality. Our data support using several β-lactam-, fluoroquinolone-, and tetracycline-class antimicrobials as first-line and alternative agents for treatment of patients with anthrax meningitis; all should achieve effective microbiologic exposures. Our data suggest antimicrobials that should not be relied on to treat suspected or documented anthrax meningitis. Furthermore, the protein synthesis inhibitors clindamycin and linezolid can decrease toxin production and may be useful components of combination therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|